SCHEMBL10043828

SCHEMBL10043828

Cc1ccc(NC(=O)Nc2ccc(C)c(-c3cc4cnc(C)cc4n(C)c3=O)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.48
NPC1 O15118 8/20 0.48
SYK P43405 1/20 0.43
MAPT P10636 6/20 0.42
IMPDH2 P12268 2/20 0.42
SMN1; SMN2 Q16637 7/20 0.41
POLB P06746 3/20 0.41
AHR P35869 1/20 0.40
TP53 P04637 2/20 0.39
GBA1 P04062 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
STAT1 P42224 1/20 0.39
KRAS P01116 1/20 0.39
RAF1 P04049 1/20 0.39
BRAF P15056 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043821 0.94 SYK (0.49) RAB9ANPC1SYKMAPTIMPDH2
SCHEMBL10043835 0.91 HTR2A (0.43) RAB9ANPC1SYKMAPTSMN1; SMN2
SCHEMBL10043825 0.91 FGFR1 (0.48) RAB9ANPC1MAPTSMN1; SMN2POLB
SCHEMBL10043857 0.90 POLB (0.45) RAB9ANPC1SYKMAPTSMN1; SMN2
SCHEMBL10043705 0.90 MAPT (0.54) RAB9ANPC1SYKMAPTSMN1; SMN2
SCHEMBL501986 0.89 NPC1 (0.47) RAB9ANPC1SYKMAPTSMN1; SMN2
SCHEMBL10043829 0.89 SYK (0.41) RAB9ANPC1SYKMAPTKRAS
SCHEMBL10043948 0.88 MAPK14 (0.42) RAB9ANPC1SYKMAPTPOLB
SCHEMBL10043839 0.88 SYK (0.47) RAB9ANPC1SYKMAPTKRAS
SCHEMBL10043830 0.88 SMARCA2 (0.48) RAB9ANPC1SYKMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SYK 42/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SYK 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.